Phenomix Corporation, Former Highflying Diabetes Drugmaker, Shuts Down After Forest Laboratories, Inc. (FRX) Walks
10/26/2010 8:10:09 AM
More...
|
Phenomix Corporation Announces Positive Results from a Phase 3 Study of Dutogliptin in Type 2 Diabetes Mellitus
4/20/2010 6:21:02 AM
More...
|
Phenomix Corporation Grants Chiesi Farmaceutici SpA European Rights to Dutogliptin for Diabetes in Deal Worth Up to $191 Million
12/2/2009 9:03:47 AM
More...
|
Phenomix Corporation Implements etrials’ Trial Intelligence EDC to Improve Data Quality, Integrate Data in Real-time
3/31/2009 10:25:21 AM
More...
|
Phenomix Corporation Initiates Phase 1a Clinical Trial of Hepatitis C Protease Inhibitor PHX1766
10/28/2008 8:41:17 AM
More...
|
Forest Laboratories, Inc. (FRX) (JOBS) and Phenomix Corporation in $340 Million Diabetes Deal
10/23/2008 6:38:42 AM
More...
|
Phenomix Corporation Announces PHX1149 Phase 2b Clinical Trial Results for Type 2 Diabetes
5/19/2008 10:04:08 AM
More...
|
Phenomix Corporation Files for $86.25 Million IPO
1/28/2008 7:04:31 AM
More...
|
Phenomix Corporation Hires John Crawford as Chief Financial Officer and Appoints Arlene Morris to Board of Directors
10/17/2007 11:03:22 AM
More...
|
Phenomix Corporation Initiates Phase 2b Clinical Trial of PHX1149 for Type 2 Diabetes; Will Present PHX1149 Data at EASD
9/11/2007 9:54:36 AM
More...
|
|